Mar 12, 201918 minAnlysis of Bio - Pharma in East Asia - Trends ReportBiopharmaceutical Report III Issue6_April 2015 Featured Story of Korean Pharma: Hanwha confirms abandoning bid for Dow Chemical basic...
Mar 12, 20195 minAstellas/Medivation's Xtandi has questionable potential to displace bicalutamideBiopharmaceutical Report II Issue6_April 2015 Astellas (TYO:4503)/Medivation's (NASDAQ:MDVN) Phase II TERRAIN study topline data on...
Mar 12, 20196 minSpark's LCA2 gene therapy is likely to have greater benefit for younger patientsBiopharmaceutical Report I Issue6_April 2015 Spark Therapeutics' (NASDAQ:ONCE) subretinal gene therapy injection of SPK-RPE65, is likely...
Mar 12, 20195 minBiosimilar Reference Products Expected to GrowBiopharmaceutical Report II Issue5_February 2015 • Logistic complications create high demand for the expertise of comparator suppliers •...
Mar 12, 20194 minDiabetic Neuropathy Patient Stratification, Chances BoostedBiopharmaceutical Report I Issue5_February 2015 • Phase II signals encouraging for positive Phase III translation • Capsaicin as...
Mar 12, 20196 minJ&J may suffer over AbbVie,Amgen in renewed biologic USpayer contracts as Celltrion’sbiosimilar loomBiopharmaceutical Report II Issue4_November 2014 • Remsima use may be forced ahead of Remicade, but not Humira or Enbrel • ...
Mar 12, 20195 minArray/Novartis’ binimetinib expected to best chemotherapy in Phase III trial despite protocol changeBiopharmaceutical Report I Issue4_November 2015 • Enrollment criteria expanded mid-trial to reflect shifting treatment landscape • ...
Mar 12, 20196 minThe Unrealized Potential of Stem Cell TherapyBiopharmaceutical Report III Issue3_September 2014 Over the last decade or so, I have observed a tempering of what was once a large and...
Mar 12, 20195 min*Novartis’ LCZ696 for CHFdraws approval optimism aftermeeting difficult Phase IIIendpoints Biopharmaceutical Report II Issue3_September 2014 • Superiority to standard therapy bodes well for approvals • Regulators may require...
Mar 12, 20195 min*Celgene's Revlimid has experts optimistic about potential in Phase III non-del (5q) MDS trial in trBiopharmaceutical Report I Issue3_September 2014 • Historical responses meaningful, but approvability based on transfusion changes...
Mar 12, 20194 min*Merck's Phase III tecemotide vaccine trial in NSCLC in Asian patients could show benefit, but ..Biopharmaceutical Report II Issue2_May 2014 • Marginal OS benefit found in Asian patients in previous trial lends optimism • Vaccine...
Mar 12, 20196 minAstraZeneca’s pipeline projections a tough sell, Pfizer will struggle to drive combined valueBiopharmaceutical Report I Issue2_May 2014 • Valuations unreliable given large timeframe to market • Likely EU/US pricing pressures...
Mar 12, 20194 minAstraZeneca's Phase I/II AZD9291 shows promise in EGFR inhibitor refractory patients - oncologistsBiopharmaceutical Report III Issue1_March 2014 "Targets T790M mutation to overcome EGFR inhibitor resistance Could be effective in the...
Mar 12, 20194 minLife science industry's record-setting pace of deals unlikely to end anytime soonBiopharmaceutical Report II Issue1_March 2014 • Recent IPOs have started to lose some steam, one banker notes • Tax inversion key...
Mar 12, 201912 minBiopharma in 2013: A Rising TideBiopharmaceutical Report I Issue1_March 2014 Big launches, clinical success in key therapeutic areas like cancer immunotherapy, and...